$603 Million is the total value of Cormorant Asset Management, LP's 71 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 44.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TBPH | Sell | THERAVANCE BIOPHARMA INC | $37,848,000 | -27.9% | 950,000 | -33.3% | 6.27% | -17.7% |
| NVRO | Sell | NEVRO CORP | $20,096,000 | -38.7% | 270,000 | -22.9% | 3.33% | -30.1% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $19,526,000 | -18.2% | 720,000 | -10.0% | 3.24% | -6.6% |
| ANAB | Sell | ANAPTYSBIO | $19,131,000 | -23.0% | 799,469 | -10.7% | 3.17% | -12.1% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $18,641,000 | -22.3% | 367,900 | -38.7% | 3.09% | -11.3% |
| NERV | Sell | MINERVA NEUROSCIENCES INC | $17,677,000 | -5.4% | 1,997,412 | -13.5% | 2.93% | +8.0% |
| MYOK | Sell | MYOKARDIA INC | $13,100,000 | -11.8% | 1,000,000 | -11.5% | 2.17% | +0.6% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $11,500,000 | -11.5% | 250,000 | -16.7% | 1.91% | +1.1% |
| ALDR | Sell | ALDER BIOPHARMACEUTICALS INC | $10,305,000 | -54.9% | 900,000 | -18.0% | 1.71% | -48.5% |
| HRTX | Sell | HERON THERAPEUTICS INC | $7,894,000 | -56.1% | 570,000 | -52.5% | 1.31% | -50.0% |
| ARDX | Sell | ARDELYX INC | $7,256,000 | -70.2% | 1,422,738 | -26.0% | 1.20% | -65.9% |
| BOLD | Sell | AUDENTES THERAPEUTICS, INC | $6,189,000 | -14.5% | 323,545 | -23.8% | 1.03% | -2.4% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $5,655,000 | -35.4% | 500,000 | -26.9% | 0.94% | -26.3% |
| IVTY | Sell | INVUITY INC | $5,075,000 | -15.6% | 700,000 | -7.5% | 0.84% | -3.7% |
| JNCE | Sell | JOUNCE THERAPEUTICS INC | $5,047,000 | -47.2% | 359,738 | -17.3% | 0.84% | -39.7% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $4,204,000 | -36.5% | 1,539,750 | -23.0% | 0.70% | -27.5% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $3,759,000 | -71.6% | 202,079 | -58.1% | 0.62% | -67.6% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $3,520,000 | +12.8% | 400,000 | -33.3% | 0.58% | +28.7% |
| REPH | Sell | RECRO PHARMA INC | $2,343,000 | -54.6% | 333,200 | -43.5% | 0.39% | -48.2% |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -700,000 | -100.0% | -0.06% | – |
| GLYC | Exit | GLYCOMIMETICS INC | $0 | – | -287,031 | -100.0% | -0.23% | – |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -81,000 | -100.0% | -0.24% | – |
| TIG | Exit | TIGENIXsponsored ads | $0 | – | -129,032 | -100.0% | -0.29% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -520,183 | -100.0% | -0.31% | – |
| AVXS | Exit | AVEXIS INC | $0 | – | -30,000 | -100.0% | -0.33% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -140,000 | -100.0% | -0.35% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -100,000 | -100.0% | -0.41% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -240,403 | -100.0% | -0.48% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -75,000 | -100.0% | -0.74% | – |
| INCR | Exit | INC RESH HLDGS INCcl a | $0 | – | -200,000 | -100.0% | -1.33% | – |
| CBPO | Exit | CHINA BIOLOGIC PRODUCTS INC | $0 | – | -100,000 | -100.0% | -1.45% | – |
| ZYNE | Exit | ZYNERBA PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -1.46% | – |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -589,175 | -100.0% | -1.84% | – |
| CRBP | Exit | CORBUS PHARMACEUTICALS HLDGS | $0 | – | -1,686,100 | -100.0% | -2.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.